A dengue fever vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases is entering a Phase III trial in Brazil that may enroll nearly 17,000 people in 13 cities. The trial is expected to last 5 years, but investigators hope for early efficacy indications in less than two years. The São Paulo-based Butanatan Institute is sponsoring the trial and has licensed the vaccine technology, dubbed TV003. More